Morgan Stanley initiated coverage on Heartflow with a new price target
$HTFL
Medical/Dental Instruments
Health Care
Morgan Stanley initiated coverage of Heartflow with a rating of Equal-Weight and set a new price target of $35.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/2/2025 | $36.00 | Overweight | Analyst |
| 9/2/2025 | $38.00 | Overweight | Piper Sandler |
| 9/2/2025 | $35.00 | Buy | Stifel |
| 9/2/2025 | $35.00 | Buy | Canaccord Genuity |
| 9/2/2025 | $35.00 | Equal-Weight | Morgan Stanley |
MOUNTAIN VIEW, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced Heartflow Plaque Analysis is now covered by Aetna across all lines of business, including Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans. Aetna is the fourth major national commercial insurer to update its policies to cover Heartflow Plaque Analysis to fully align with the guidelines issued by radiology benefit manager EviCore, following similar decisions by Humana, Cigna, and UnitedHealthcare. Heartflow Plaque Analysis is covered for the majority of insured lives across the United States.
MOUNTAIN VIEW, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 13, 2026, at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived version of the presentation will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com. About Heartflow's Technology and ResearchHeartflow's technology is redefining precision cardiovascular care through clinically-proven AI an
MOUNTAIN VIEW, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), announced the American College of Cardiology (ACC) and the American Heart Association (AHA) published new scientific statements supporting the prognostic value of quantifying coronary plaque and reinforcing the critical role of the coronary computed tomography angiography (CTA) + Heartflow pathway in CAD patient management. The ACC's consensus recommendations, published this week in JACC: Cardiovascular Imaging, highlight the importance of quantitative plaque assessment and underscore the benefits of adopting AI-powered Heartflow
Analyst initiated coverage of Heartflow with a rating of Overweight and set a new price target of $36.00
Piper Sandler initiated coverage of Heartflow with a rating of Overweight and set a new price target of $38.00
Stifel initiated coverage of Heartflow with a rating of Buy and set a new price target of $35.00
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
4 - Heartflow, Inc. (0001464521) (Issuer)
10-Q - Heartflow, Inc. (0001464521) (Filer)
8-K - Heartflow, Inc. (0001464521) (Filer)
SCHEDULE 13G - Heartflow, Inc. (0001464521) (Subject)
4 - Heartflow, Inc. (0001464521) (Issuer)
MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (NASDAQ:HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025. Those interested in listening to the conference call should register online using this link. Once registered, participants will receive dial-in numbers and a unique PIN to join the call. Participants are encouraged to register more than 15 minutes prior to the start of t